A new study indicates that cerebrospinal fluid levels of specific reactive astrocyte biomarkers reflect different Alzheimer disease pathologies in the brain.doi:10.1038/s41582-022-00713-xHeather WoodNature Reviews NeurologyNature Publishing Group UKNature Reviews Neurology...
Wood, H. Reactive astrocyte biomarkers mirror Alzheimer disease pathology. Nat Rev Neurol 18, 575 (2022). https://doi.org/10.1038/s41582-022-00713-x Download citation Published23 August 2022 Issue DateOctober 2022 DOIhttps://doi.org/10.1038/s41582-022-00713-x Springer Nature Limited Associated...
Therefore, the nature of their contribution in humans has not yet been defined, probably because of confounding factors related to the use of postmortem tissues, the brain regions analyzed, the severity of the disease in the subjects studied, differ- ences in pharmacological treat...
Neuroinflammation, particularly early astrocyte reactivity, is a significant driver of Alzheimer disease (AD) pathogenesis. It is unclear how the levels of astrocyte biomarkers change in patients across the AD continuum and which best reflect AD-related change. We performed a systematic review and ...
biomarkerschitinase-3-like protein 1 (YKL-40)glial fibrillary acidic protein (GFAP)preclinical Alzheimer's diseasestructural equation modelingINTRODUCTION We studied how biomarkers of reactive astrogliosis mediate the pathogenic cascade in the earliest Alzheimer's disease (AD) stages. METHODS W...
Conclusions Astrocyte-derived proteins like GFAP and S100B can be reliably detected in CSF and might serve as markers for late pathophysiological events in the course of the disease. Additional measurement of astroglial biomarkers might allow an improved pathobiological staging of聽AD....